Abstract
Recent updates of the guidelines on the prevention of human immunodeficiency virus mother-to-child transmission have shortened the neonatal zidovudine prophylactic regimens from 6 to 4 weeks. We present a prospective observational study in a large cohort of mother-infant pairs and report that the 4-week regimen allows an earlier recovery of the anemia in these otherwise healthy infants.
| Original language | English |
|---|---|
| Pages (from-to) | 376-379 |
| Number of pages | 4 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 29 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Apr 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hematologic toxicity
- Human Immunodeficiency virus
- Pediatrics
- Neonatal prophylaxis
- Zidovudine
Fingerprint
Dive into the research topics of 'Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver